MedTrace Logo

Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?

NCT01605370 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2014-05-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate if a drug called nebivolol can reverse inappropriate left ventricular mass (LVM) when compared to the standard of care drug metoprolol.

Conditions

Interventions

DRUG

Nebivolol

Nebivolol 2.5 mg once daily

DRUG

Metoprolol succinate

Metoprolol succinate 50 mg once daily

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Marek Belohlavek, MD, PhD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01605370 on ClinicalTrials.gov